

*fulfilling lives*



## **Q2 2018 Results Presentation**

**24 May 2018**

# Disclaimer

**THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION. IT IS PROVIDED AS INFORMATION ONLY.**

This presentation is furnished only for the use of the intended recipient, and may not be relied upon for the purposes of entering any transaction. By attending the bond call presentation, you are agreeing to be bound by these restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Certain information herein (including market data and statistical information) has been obtained from various sources. We do not represent that it is complete or accurate. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of the matters described herein. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent that they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

This presentation does not constitute an offer or an agreement, or a solicitation of an offer or an agreement, to enter any transaction (including for the provision of any services) and does not constitute an offer or invitation to subscribe for, or purchase any securities, and nothing contained herein shall form the basis of any contract or commitment whatsoever.

The information contained herein does not constitute investment, legal, accounting, regulatory, taxations or other advice and the information does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation, or particular needs. You are solely responsible for forming your own opinions and conclusion on such matters and the market and for making your own independent assessment of the information herein. You are solely responsible for seeking independent professional advice in relation to the information and any action taken on the basis of the information. Investors and prospective investors in the securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such issuer and the nature of the securities.

This presentation includes certain financial data that are “non-IFRS financial measures”. These non-IFRS financial measures do not have a standardised meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with IFRS. Although we believe these non-IFRS financial measures provide useful information to users in measuring the financial performance and condition of the business, you are cautioned not to place undue reliance on any non-IFRS financial measures included in this presentation. This presentation contains certain data and forward looking statements regarding the U.K. economy, the markets in which we operate and its position in the industry that were obtained from publicly available information, independent industry publications, and other third party data. We have not independently verified such data and forward looking statements and cannot guarantee their accuracy or completeness.

# Contents

- Overview
- Q2 2018 Financial Performance
- Cash Flow
- Funding and Leverage
- Residential Care Services
- Health Care
- Appendix - Revenue/EBITDA Bridge

- **Overall performance ahead of management expectations**
  - Continued growth in Residential Care driven mainly by new homes
  - Strong Health Care performance delivering on new business and efficiency programmes
  - Leverage continues to trend downward as EBITDA LTM builds
  
- **Residential Care**
  - Strong underlying revenue growth due to maturing occupancy in new build homes and progressive self-pay mix
  - Occupancy softening in Q2 due to sector wide high winter mortality rates
  - Two new build self-funded homes opened in Q2 - on target to open two more in H2 (total of six in FY 2018)
  - Four care homes taken out of portfolio; two local authority handed back, one sold (£3.9m proceeds), one closed pending structural investigation
  - Significant landlord lease negotiation completed – £1m p.a. rent saving in exchange for £6.5m cash outlay (£3.1m freehold purchases, £3.4m lease premium)
  - Strong new home pipeline - ten new homes in construction potentially opening in FY 2019
  - Best quality performance amongst five largest operators – 83% of homes rated at least 'Good' by CQC with two 'Outstanding'
  - CMA review consumer law findings available in summer 2018 – impact to be considered once available

## ■ Health Care

- Strong Revenue growth from new prison healthcare contracts with improving margin
- Efficiency and procurement programmes underpinning a strong financial result in Electives despite variable activity levels as a result of seasonality and ongoing referral management by NHS – waiting lists now longest since 2009
- Strategic partnership model with Southampton NHS Trust to commence in April utilising theatre capacity – similar opportunities being developed with other Trusts
- Self-pay option for patients now launched
- A challenging winter period in Urgent Care with increased cost required to match demand. The market remains challenging but integrated services now key to delivering value for CCGs and patients. Care UK well placed to leverage our call centre capability

## ■ Strategic Review

- We continue to evaluate strategic options for the long term future and continued growth of both businesses. A full range of potential scenarios, including property based options, are under consideration

# Q2 2018 Financial Performance

## ■ Revenue and Adjusted EBITDA

- Revenue increased by £7.9m (5%) with strong underlying growth in RCS £8.1m (excluding discontinued homes) and new prison contracts £7.0m more than offsetting seasonal reduction in Electives and contract exits in Health Care
- Adjusted EBITDA increased £1.7m (14%) to £12.7m - H1 EBITDA of £23.3m represents year on year growth of 31%
- Pro forma Adjusted EBITDA of £14.6m, £2.4m higher than Q2 2017 with higher start-up losses following new home openings
- Health Care EBITDA ahead of prior year by £1.6m. Improved profitability in Secondary Care from efficiency and cost saving initiatives with greater flexibility to respond to demand. Prison contracts delivering improved margin through service optimisation
- Year on year RCS pro forma EBITDA growth of 8.3% to £9.1m. Decline of £0.9m from Q1 2018 due in part to discontinued homes and partly as a result of the sector wide seasonal occupancy dip

## ■ Finance costs

- Net financing expenses of £3.9m - in line with prior year from stable debt and interest cost

## ■ Net debt and leverage

- Reported leverage ahead of expectations at 6.0x (5.3x Pro forma) from progressive EBITDA LTM growth
- Net debt marginally higher than prior year and prior quarter at £268m

# Q2 2018 Financial Performance

| £m                               | Q2           |       |          | Q1    |          |
|----------------------------------|--------------|-------|----------|-------|----------|
|                                  | 2018         | 2017  | Movement | 2018  | Movement |
| <b>Revenue</b>                   |              |       |          |       |          |
| Residential Care                 | 78.8         | 73.0  | 5.8      | 79.6  | (0.8)    |
| Health Care                      | 91.8         | 89.7  | 2.1      | 90.3  | 1.5      |
| <b>Total</b>                     | <b>170.6</b> | 162.7 | 7.9      | 169.9 | 0.7      |
| <b>Adjusted EBITDA</b>           |              |       |          |       |          |
| Residential Care                 | 7.2          | 7.3   | (0.1)    | 8.2   | (1.0)    |
| Health Care                      | 6.7          | 5.1   | 1.6      | 3.8   | 2.9      |
| Other                            | (1.2)        | (1.3) | 0.1      | (1.4) | 0.2      |
| <b>Reported Adjusted EBITDA</b>  | <b>12.7</b>  | 11.1  | 1.6      | 10.6  | 2.1      |
| Start-up Losses                  | 1.9          | 1.1   | 0.8      | 1.8   | 0.1      |
| <b>Pro-forma Adjusted EBITDA</b> | <b>14.6</b>  | 12.2  | 2.4      | 12.4  | 2.2      |

- Continued underlying growth in RCS; reported performance diluted by start-up losses and discontinued homes
- Strong H1 performance in HC significantly ahead of expectations
- RCS: Excluding discontinued homes revenue up 11.6% year on year. Pro forma Adjusted EBITDA increased £0.7m to £9.1m reflecting the continuing maturity of the new, self-pay orientated homes.
- HC: Prisons performing strongly both from new business and underlying profitability. Secondary Care Electives delivering improved profitability from procurements savings and efficiency programmes

# Cash Flow

| £m  | Q2 2018      | Q2 2017     | Movement     |
|---|--------------|-------------|--------------|
| Adjusted operating profit                                   | 5.1          | 4.9         | 0.2          |
| Depreciation and other non-cash movements                   | 6.6          | 6.1         | 0.5          |
| Change in working capital and non-recurring items           | (0.1)        | 4.0         | (4.1)        |
| <b>Cash flow from operations</b>                            | <b>11.6</b>  | <b>15.0</b> | <b>(3.4)</b> |
| Business disposals, net of cash disposed                    | -            | 0.2         | (0.2)        |
| Cash flows resulting from financing activities and taxation | (4.3)        | (4.1)       | (0.2)        |
| Capital expenditure, net of disposal proceeds               | (8.6)        | (9.3)       | 0.7          |
| Loans to parent & related party undertakings                | -            | (0.2)       | 0.2          |
| Pension deficit contribution                                | (2.5)        | -           | (2.5)        |
| <b>Movement in net debt arising from cash flows</b>         | <b>(3.8)</b> | <b>1.6</b>  | <b>(5.4)</b> |
| Other non-cash movements in net debt                        | (0.3)        | (0.3)       | -            |
| <b>Total movement in net debt</b>                           | <b>(4.1)</b> | <b>1.3</b>  | <b>(5.4)</b> |

- Net debt £5.4m higher than prior year (£4.1m higher than Q1)
- Significant individual items in the quarter include:
  - Lease portfolio renegotiation £6.5m (£3.1m freehold acquisition; £3.4m lease premium)
  - Defined benefit pension scheme contribution £2.5m
- Capital expenditure £8.6m in Q2 (net of £3.9m disposal proceeds):
  - Maintenance capex £7.1m (H1 £11.7m) – Q2 includes significant Secondary Care investment in Endoscopy equipment
  - Expansionary capex £5.4m (H1 £7.6m) – Q2 includes two freehold purchases referenced above
  - Care home sale proceeds received £3.9m



# Funding and Leverage

| Continuing Operations                                  |              |              |              |              |
|--|--------------|--------------|--------------|--------------|
| Financial Leverage £m                                  | Q3 2017      | Q4 2017      | Q1 2018      | Q2 2018      |
| LTM Adjusted EBITDA                                    | 39.6         | 38.7         | 42.6         | 44.2         |
| LTM Pro forma Adjusted EBITDA <sup>1</sup>             | 43.8         | 43.6         | 48.4         | 50.8         |
| Total Net Debt / Adjusted EBITDA                       | 6.71x        | 6.65x        | 6.20x        | 6.07x        |
| Total Net Debt / Pro forma Adjusted EBITDA             | 6.07x        | 5.90x        | 5.46x        | 5.28x        |
| Net Debt £m  | Q3 2017      | Q4 2017      | Q1 2018      | Q2 2018      |
| Senior Secured 1 <sup>st</sup> Lien Notes              | 230.0        | 230.0        | 230.0        | 230.0        |
| Senior Secured 2 <sup>nd</sup> Lien Notes <sup>2</sup> | 37.6         | 37.6         | 37.6         | 37.6         |
| RCF  | 11.0         | 4.0          | 17.0         | 22.0         |
| <b>Total Debt</b>                                      | <b>278.6</b> | <b>271.6</b> | <b>284.6</b> | <b>289.6</b> |
| Cash   | (10.3)       | (12.0)       | (18.4)       | (19.6)       |
| Deferred financing costs                               | (2.6)        | (2.2)        | (1.9)        | (1.6)        |
| <b>Net Debt</b>  | <b>265.7</b> | <b>257.4</b> | <b>264.3</b> | <b>268.4</b> |
| Liquidity (Undrawn RCF <sup>3</sup> + cash)            | 64.3         | 73.0         | 66.4         | 62.6         |

<sup>1)</sup> Pro forma Adjusted EBITDA, excluding new home start-up losses of the RCS division.

<sup>2)</sup> Excludes £5m held in Treasury by Care UK's parent Health & Social Care Finance Ltd.

<sup>3)</sup> Full utilisation of RCF is restricted to 115% of mortgaged property portfolio NBV


# Residential Care Services

|                                  | Q2 2018     | Q2 2017      | Movement         | Q1 2018      | Movement         |
|----------------------------------|-------------|--------------|------------------|--------------|------------------|
| <b>Revenue (£m)</b>              | <b>78.8</b> | <b>73.0</b>  | <b>5.8</b>       | <b>79.6</b>  | <b>(0.8)</b>     |
| <b>Adjusted EBITDA (£m)</b>      | <b>7.2</b>  | <b>7.3</b>   | <b>(0.1)</b>     | <b>8.2</b>   | <b>(1.0)</b>     |
| <i>EBITDA Margin (%)</i>         | <i>9.1%</i> | <i>10.0%</i> | <i>(0.9)ppts</i> | <i>10.3%</i> | <i>(1.2)ppts</i> |
| Start-up Losses                  | 1.9         | 1.1          | 0.8              | 1.8          | 0.1              |
| <b>Pro forma Adjusted EBITDA</b> | <b>9.1</b>  | <b>8.4</b>   | <b>0.7</b>       | <b>10.0</b>  | <b>(0.9)</b>     |
| Total Beds                       | 7,729       | 7,437        | 292              | 7,858        | (129)            |
| Total Financial occupancy (%)    | 85.4%       | 89.0%        | (3.6)ppts        | 87.3%        | (1.9)ppts        |
| Average weekly fee (£)           | £875        | £822         | £53              | £868         | £7               |
| Labour to sales ratio (%)        | 60.7%       | 58.4%        | 2.3ppts          | 58.9%        | 1.8ppts          |


- Continued growth in revenue; up 7.9% on prior year; 11.6% excluding discontinued homes – generated by progressive maturing of occupancy in new homes and combination of increased fee rates and self-funding mix within established homes
- Revenue growth on prior quarter excluding discontinued homes is £0.6m; impacted by sector wide dip in occupancy
- Adjusted EBITDA impacted by start up losses – on a Pro Forma basis: EBITDA increased £0.7m year on year
- £1.0m reduction in Adjusted EBITDA against prior quarter due in part to discontinued homes and partly as a result of occupancy dip
- Total occupancy diluted by scale of new homes from (89% to 85% vs PY). Excluding recent new builds occupancy levels are above 90%.

# Residential Care Services Key Performance Indicators

Number of Beds



Financial Occupancy %




- Approx. 130 net bed reduction in the quarter – two new homes opened off-set by the four homes removed
- Another two new builds due to open in H2 FY 2018 will add 130 beds. Pipeline of homes in construction with aggregate bed total of over 600.
- Mature homes 1.6% dip in the quarter from high mortality rate impacting the sector
- Total financial occupancy at 85.4% for Q2 2018, diluted by lower occupancy in newly opened homes – excluding these homes, total portfolio marginally down at c.90% occupancy


# Residential Care Services

## Key Performance Indicators (Continued)

Average Weekly Fee (£)



Direct Labour as a % of Revenue



- AWF increase on prior year 6.4% - reflects annual fee increases (April each year) and continued increase in self-funding proportion
- Self-funding revenue Q2 2018: 45.5% (Q2 2017: 41.1%) – expected to achieve 50% by late 2018
- Labour to sales ratio 60.7% - 1.8 ppts increase on Q1 FY18 – approximately one third due to new home openings which have high labour ratio until occupancy builds, and two thirds attributable to sector wide occupancy reduction
- Agency cost reduced in Q2 both in absolute terms and as a proportion of revenue

|                        | Q2 2018 | Q2 2017 | Movement | Q1 2018 | Movement |
|------------------------|---------|---------|----------|---------|----------|
| Revenue (£m)           | 91.8    | 89.7    | 2.1      | 90.3    | 1.5      |
| Adjusted EBITDA (£m)   | 6.7     | 5.1     | 1.6      | 3.8     | 2.9      |
| EBITDA Margin (%)      | 7.3%    | 5.7%    | 1.6ppts  | 4.2%    | 3.1ppts  |
| Secondary care volumes | 21,704  | 21,805  | (101)    | 20,101  | 1,603    |

- Strong performance in Q2, building on Q1 – H1 EBITDA £10.5m (double prior year)
- Revenue increased £2.1m from 2017:
  - Growth driven by new prison contracts; over £7.0m of additional revenue
  - Traditional GP practice and Walk in Centre contract reductions (£1.2m)
  - Slightly lower revenue in Elective Surgery treatment centres through mix change (less major orthopaedics)
- Adjusted EBITDA of £6.7m, an increase of £1.6m (31%) on 2017
  - New prison contracts delivering the expected improved margins through service optimisation as more efficient working practices are embedded
  - Adjusted Elective Surgery EBITDA in line with prior year with more efficient cost base and procurement programme savings

# Appendix – Revenue/EBITDA Bridge

|                               |                            | Revenue           |                   | EBITDA            |                   |
|-------------------------------|----------------------------|-------------------|-------------------|-------------------|-------------------|
| £m                            |                            | Q2/17 to<br>Q2/18 | Q1/18 to<br>Q2/18 | Q2/17 to<br>Q2/18 | Q1/18 to<br>Q2/18 |
| <b>Base period</b>            |                            | <b>162.7</b>      | <b>169.9</b>      | <b>11.1</b>       | <b>10.6</b>       |
| <b>HC</b>                     | Electives                  | (3.0)             | 1.2               | -                 | 1.8               |
|                               | CATS and Diagnostics       | (0.3)             | (0.3)             | (0.2)             | (0.1)             |
|                               | Prison healthcare          | 7.0               | 0.4               | 2.4               | 1.1               |
|                               | GP and WIC's               | (1.2)             | -                 | (0.1)             | (0.1)             |
|                               | NHS 111/OOH                | (0.4)             | 0.2               | -                 | 0.4               |
|                               | Other Health Care          | -                 | -                 | (0.1)             | -                 |
|                               | Overheads                  | -                 | -                 | (0.4)             | (0.2)             |
|                               | <b>Total HC</b>            | <b>2.1</b>        | <b>1.5</b>        | <b>1.6</b>        | <b>2.9</b>        |
| <b>RCS</b>                    | RCS mature                 | 2.1               | (0.9)             | (0.5)             | (0.6)             |
|                               | RCS new (FY14-FY18)        | 5.2               | 1.4               | 0.9               | 0.2               |
|                               | Suffolk                    | 0.8               | 0.1               | 0.4               | -                 |
|                               | Discontinued homes         | (2.3)             | (1.4)             | 0.1               | (0.4)             |
|                               | Overheads                  | -                 | -                 | (0.2)             | (0.1)             |
|                               | <b>Total Pro forma RCS</b> | <b>5.8</b>        | <b>(0.8)</b>      | <b>0.7</b>        | <b>(0.9)</b>      |
|                               | New home start up losses   | -                 | -                 | (0.8)             | (0.1)             |
|                               | <b>Total Reported RCS</b>  |                   |                   | <b>(0.1)</b>      | <b>(1.0)</b>      |
| Other (net) <sup>1</sup>      |                            |                   | 0.1               | 0.2               |                   |
| <b>Group Reported Q2 2018</b> |                            | <b>170.6</b>      | <b>170.6</b>      | <b>12.7</b>       | <b>12.7</b>       |

<sup>1)</sup> Includes group functions and movements in immaterial service lines



*fulfilling lives*